Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 9,834,597 | 12/05/2017 | 2012-110 |
Chemically based protein modification methods could provide useful strategies for the generation of antibody mimics. However, the highly complex structures of antibody domains make it exceptionally difficult to modify these proteins in a single or small number of locations. This complexity includes the presence of multiple polypeptide chains, extensive disulfide networks, and critically important glycosylation patterns, all of which must remain intact to obtain biological function.
To address these problems, UC Berkeley investigators have developed novel antibody mimics by installing synthetic molecules at the N-termini of crystallizable fragment domains (Fc's) via chemical modification approaches. The synthesis leads to the production of Fc-synthetic molecule hybrids, where the Fc domains serve as building blocks to improve the pharmacokinetic properties of synthetic agents and provide them with immunological activating properties.
Synthetically modified Fc domains as building blocks for immunotherapy applications
Fusion protein, therapeutic, crystallizable fragment, drug delivery, drug discovery, antibody, polypeptide, diagnostic